Overview

Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study

Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The study will investigate the effect of PL-56 on albumin leakage and renal function (glomerular filtration rate) in patients with IgA nephropathy. It will also assess the safety of treatment with PL-56.
Phase:
Phase 2
Details
Lead Sponsor:
Calliditas Therapeutics AB
Pharmalink AB
Collaborator:
Archimedes Development Ltd
Treatments:
Anti-Inflammatory Agents
Budesonide